We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Levels of CSF Biomarkers Diagnostic for Early Phase Parkinson's Disease

By LabMedica International staff writers
Posted on 02 Sep 2013
Analysis of cerebral spinal fluid (CSF) from patients with early Parkinson's disease led to the identification of a group of proteins whose concentrations correlated with the severity of the disease and may have diagnostic and prognostic potential.

Investigators at the University of Pennsylvania (Philadelphia, USA) worked with CSF specimens obtained from 102 participants in the Parkinson's Progression Markers Initiative (PPMI) - 63 with early, untreated Parkinson's disease and 39 healthy controls. More...
CSF samples were evaluated for levels of five biomarkers: amyloid beta, total tau protein, phosphorylated tau protein, alpha-synuclein, and the ratio of total tau to amyloid beta.

The CSF biomarkers were measured by INNO-BIA AlzBio3 immunoassay (Abeta1-42, T-tau protein, and P-tau181) provided by Innogenetics Inc. (Alpharetta, GA, USA) or by an enzyme-linked immunosorbent assay (alpha-synuclein). Clinical features including diagnosis, demographic characteristics, motor, neuropsychiatric, and cognitive assessments were systematically evaluated according to the PPMI study protocol.

Results revealed that patients with early Parkinson's disease had lower levels of the biomarkers amyloid beta, tau protein and alpha-synuclein in their spinal fluid. Furthermore, those with lower concentrations of tau protein and alpha-synuclein had greater motor dysfunction. Early Parkinson's patients with low levels of amyloid beta and tau protein were more likely to be classified as having the postural instability-gait disturbance- dominant (PIGD) motor type of disease, where falling, freezing, and walking difficulties are common.

"Biomarkers for Parkinson's disease such as these could help us diagnose patients earlier, and we have now shown that the simultaneous measurement of a variety of neurodegenerative disease proteins is valuable," said senior author Dr. Leslie M. Shaw, professor of pathology and laboratory medicine at the University of Pennsylvania.

Testing of CSF for Parkinson's disease biomarkers is still in the research phase, and it will continue to be evaluated and validated with a greater number of PPMI participants.

The study was published in the August 26, 2013, online edition of the journal JAMA Neurology.

Related Links:
University of Pennsylvania
Innogenetics Inc.



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.